Abstract:Abstract Background: The incidence of early onset (EO) colorectal cancer (CRC) (age <50) is rising with a left-sided predominance. Response to chemotherapy and anti-EGFR therapies differ in left- and right-sided colon cancers after accounting for genomic differences. The intestinal microbiome may contribute to CRC pathogenesis and response to therapy; how organisms drive metastasis and treatment resistance is not known. Purpose: To define the microbiome contribution to EO-CRC and response to treatment by analyzing longitudinal samples from previously untreated patients with CRC. Methods: We designed a prospective biospecimen collection platform and selected patients with previously untreated CRC. We collected stool, biopsy or surgical tissue, and peripheral blood mononuclear cells at baseline and serially throughout treatment. Stool samples were analyzed using shotgun sequencing. Alpha diversity was calculated using the inverse Simpson index and compared between groups using the Wilcoxon signed-rank test. Beta diversity was analyzed using the Bray-Curtis dissimilarity matrix and compared using PERMANOVA. Multivariate associations between species abundance, metabolic pathway abundance and clinical covariates were performed using MaAsLin2 R package. Results: We analyzed a total of 132 stool samples from 65 patients with CRC including up to 5 samples from a single patient over time. Mean alpha diversity did not differ significantly by primary site, stage or age at diagnosis. Beta diversity was significantly different between samples from right- compared with left-sided CRC (P=.011) and pre- and post-surgery (P=.001). Beta diversity also differed significantly by diagnosis age (<50 vs. > 50) (P=.001 all samples, P=.032 baseline samples). When CRC baseline samples were examined at the species level, Blautia glucerasea was associated with right-sided primary (P<.001, Q=.1). Considering non-metastatic cases, recurrence was associated with increased Enteroscipio rubneri, Actinomyces oral taxon 448, Bacteroidales sp. and Lancefieldella parvula (P<.01, Q>0.1). We further investigated metabolic pathway associations. The superpathway of L-threonine metabolism was significantly increased in samples from patients with right-sided colon cancer at baseline (P<.001, Q=.03). Considering samples across all time points, right-sided colon cancer was associated with increased abundance of pathways associated with propanoate degradation, L-threonine metabolism, yeast NADPH production, and hydroxyphenylacetate degradation (all P<.001, Q<.05). Conclusions: The functional effects of the intestinal microbiome may underlie the distinct biology of right-sided colon cancer. Composition of the intestinal microbiome differs by age at diagnosis. Updated recurrence data will be presented. Citation Format: Melissa Lumish, Nicholas Waters, Joshua Leinwand, Asha Saxena, Anqi Dai, Teng Fei, Maggie Fox, Andre Chavez, Jonathan Bermeo, Dorina Ismailgeci, Elizabeth Benitez, Christopher Cowley, Julio Garcia-Aguilar, Martin Weiser, Andrea Cercek, Luis A. Diaz, Marcel van den Brink, Jonathan Peled, Karuna Ganesh. Shotgun sequencing of serial fecal microbiome samples in patients with colorectal cancer reveals distinct bacterial species and metabolic pathways associated with tumor sidedness and age at diagnosis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2805.

Distinct intratumoral microbiome of young-onset and average-onset colorectal cancer

Racial disparities in tumor microbiome in young-onset and average-onset colorectal cancer.

Abstract 3062: Modifiable factors and gut microbiome alteration among colorectal cancer patients

Comprehensive study of the intratumoral microbiome in early- vs. late-onset colorectal cancer: Final analysis of COSMO CRC.

Young-onset Rectal Cancer: Unique Tumoral Microbiome and Correlation With Response to Neoadjuvant Therapy

Tumoral microbial and pathway alterations associated with young-onset rectal cancer and its response to therapy.

IDDF2024-ABS-0170 Metagenomic Analyses Highlight Strain-Level, Age-Independent and Immunotherapy-Associated Microbial Signatures in Colorectal Cancer

Dysbiosis of human gut microbiome in young-onset colorectal cancer

Abstract 2805: Shotgun sequencing of serial fecal microbiome samples in patients with colorectal cancer reveals distinct bacterial species and metabolic pathways associated with tumor sidedness and age at diagnosis

Consistent signatures in the human gut microbiome of old- and young-onset colorectal cancer

Dysbiosis of human tumor microbiome and aberrant residence of Actinomyces in tumor-associated fibroblasts in young-onset colorectal cancer

Abstract 2807: Distinctive microbiome signatures in colorectal cancer: A comparative metagenomic analysis

Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer

Dysbiosis Signature of Fecal Microbiota in Colorectal Cancer Patients

Tumor-Associated Microbiota in Proximal and Distal Colorectal Cancer and Their Relationships With Clinical Outcomes

Abstract 758: Comparative Microbiome Analysis of Paired Mucosal and Fecal Samples in Korean Colorectal Cancer Patients

Immune Microenvironment in Sporadic Early-Onset versus Average-Onset Colorectal Cancer

Tumor microbiome differences in early-onset versus average-onset pancreatic adenocarcinoma.

Single-Cell RNA Sequencing Reveals Heterogeneity in the Tumor Microenvironment between Young-Onset and Old-Onset Colorectal Cancer

Oncomicrobial Community Profiling Identifies Clinicomolecular and Prognostic Subtypes of Colorectal Cancer

Abstract 5910: Prospective Platform to Define Microbiome Correlates of Metastasis and Therapy Resistance in Early Onset and Average Onset Gastrointestinal Cancers